Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma

This study has been completed.
Information provided by (Responsible Party):
National Cancer Institute (NCI) Identifier:
First received: June 2, 2005
Last updated: April 4, 2017
Last verified: April 2017
This phase II trial studies how well depsipeptide (romidepsin) works in treating patients with metastatic or unresectable soft tissue sarcoma. Drugs used in chemotherapy, such as depsipeptide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

Condition Intervention Phase
Adult Alveolar Soft-part Sarcoma
Adult Angiosarcoma
Adult Epithelioid Sarcoma
Adult Extraskeletal Chondrosarcoma
Adult Extraskeletal Osteosarcoma
Adult Fibrosarcoma
Adult Leiomyosarcoma
Adult Liposarcoma
Adult Malignant Fibrous Histiocytoma
Adult Malignant Hemangiopericytoma
Adult Malignant Mesenchymoma
Adult Neurofibrosarcoma
Adult Rhabdomyosarcoma
Adult Synovial Sarcoma
Gastrointestinal Stromal Tumor
Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Recurrent Adult Soft Tissue Sarcoma
Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Stage III Adult Soft Tissue Sarcoma
Stage IV Adult Soft Tissue Sarcoma
Drug: romidepsin
Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: No masking
Primary Purpose: Treatment
Official Title: A Phase II Study of Single Agent Depsipeptide (FK228) in Metastatic or Unresectable Soft Tissue Sarcomas

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Objective Tumor Response (Complete and Partial) [ Time Frame: While on treatment - max of 16 months ]
    Estimated as the proportion of participants with partial and complete responders.

  • Time to Progression [ Time Frame: Until disease progression - max of 48 months ]
    Months from first treatment until the date of progression

  • Toxicity as Assessed Using the Expanded Common Toxicity Criteria Version 3 [ Time Frame: During treatment (max of 16 months) and for 1 month following treatment ]

    The outcome reported here is the number (%) of participants who experienced grade 3 or greater toxicity while on study.

    A summary of the individual toxicities can be found in the AE/SAE results.

Secondary Outcome Measures:
  • Survival [ Time Frame: Max of 98 months ]
    Months from first treatment until death or the last date of contact

Enrollment: 40
Actual Study Start Date: January 7, 2005
Study Completion Date: October 23, 2008
Primary Completion Date: October 23, 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment (single-agent depsipeptide)
Patients receive depsipeptide (romidepsin) intravenously (IV) over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 6 additional courses beyond documentation of CR.
Drug: romidepsin
DEP is administered at a dose of 13 mg/m2 as a 4-hour intravenous infusion in the outpatient setting.
Other Names:
  • FK228
  • FR901228
  • Istodax

Detailed Description:


I. To estimate the response rates of metastatic or unresectable soft tissue sarcomas to single-agent depsipeptide.

II. To estimate the time to progression of metastatic or unresectable soft tissue sarcomas to single-agent depsipeptide.

III. To evaluate the scope and extent of acute toxicities associated with single-agent depsipeptide when given to patients with soft tissue sarcomas.

OUTLINE: This is a multicenter study.

Patients receive depsipeptide (romidepsin) intravenously (IV) over 4 hours on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 6 additional courses beyond documentation of CR.

After completion of study treatment, patients are followed up every 2 months.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically or cytologically confirmed soft tissue sarcoma (STS), including, but not limited to, the following histologies:

    • Gastrointestinal stromal tumors (GIST)

      • Refractory to imatinib mesylate
    • Desmoplastic small round cell tumors
    • Clear cell sarcoma
    • Extraskeletal osteosarcoma*
    • Extraskeletal Ewing's sarcoma*
    • Extraskeletal (myxoid) chondrosarcoma*
  • Secondary STS (e.g., radiation-induced STS or neurofibrosarcoma due to neurofibromatosis) allowed
  • Metastatic or unresectable disease
  • No standard curative therapy exists
  • Patients with GIST must have received and progressed on imatinib mesylate
  • Measurable disease, defined as ≥ 1 unidimensionally measurable lesion ≥ 20 mm by conventional techniques OR ≥ 10 mm by spiral CT scan
  • No known brain metastases
  • Performance status - Eastern Cooperative Oncology Group (ECOG) 0-2
  • Performance status - Karnofsky 50-100%
  • More than 3 months
  • White blood cells (WBC) ⥠3,000/mm^3
  • Absolute neutrophil count ≥ 1,500/mm^3
  • Platelet count ≥ 100,000/mm^3
  • Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ⤠2.5 times upper limit of normal (ULN)
  • Bilirubin normal
  • Creatinine < 1.5 times ULN
  • Creatinine clearance ≥ 60 mL/min
  • QTc ≤ 480 msec

Exclusion Criteria:

  • No cardiac abnormalities (e.g., congenital long QT syndrome)
  • No myocardial infarction within the past year
  • No history of coronary artery disease (e.g., angina Canadian Class II-IV or positive stress imaging study)
  • No cardiac ischemia (ST depression >2 mm) by electrocardiogram (ECG)
  • No New York Heart Association Class II-IV congestive heart failure
  • Ejection fraction > 50% by multi gated acquisition scan (MUGA) scan or echocardiogram
  • No history of sustained ventricular tachycardia, ventricular fibrillation, Torsades de Pointes, or cardiac arrest unless controlled by an automatic implantable cardioverter defibrillator
  • No hypertrophic or restrictive cardiomyopathy from prior treatment or other causes
  • No significant left ventricular hypertrophy
  • No uncontrolled hypertension (i.e., blood pressure ≥ 160/95 mm Hg)
  • No cardiac arrhythmia requiring anti-arrhythmic medication

    • Beta blocker or calcium channel blocker allowed
    • Patients on digitalis that cannot be discontinued not allowed
  • No Mobitz II second degree block without a pacemaker (first degree or Mobitz I second degree block, bradyarrhythmias, or sick sinus syndrome require Holter monitoring and evaluation by cardiology)
  • No uncontrolled dysrhythmia
  • No poorly controlled angina
  • No other cardiac disease
  • No history of allergic reaction attributed to compounds of similar chemical or biological composition to FR901228
  • No ongoing or active infection
  • No iatrogenic immune deficiency or immune deficiency secondary to an underlying disorder
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • Potassium ≥ 4.0 mmol/L
  • Magnesium ≥ 2.0 mg/dL
  • No other uncontrolled illness
  • No psychiatric illness or social situation that would preclude study compliance
  • No concurrent anticancer biologic agents
  • No more than 1 prior chemotherapy regimen for sarcoma

    • Adjuvant chemotherapy preceding disease relapse is considered 1 prior chemotherapy regimen
    • Patients with GIST may have received up to 3 prior chemotherapy regimens comprising imatinib mesylate and/or sunitinib malate provided no other chemotherapy agents were used
  • No prior FR901228 (depsipeptide)
  • At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)
  • No prior cumulative doxorubicin dose > 500 mg/m^2
  • No other concurrent anticancer chemotherapy
  • At least 4 weeks since prior radiotherapy
  • No concurrent anticancer radiotherapy
  • At least 4 weeks since prior surgery
  • No prior organ transplantation
  • Recovered from all prior therapy
  • No concurrent medications that cause QTc prolongation
  • No concurrent combination highly active anti-retroviral therapy for HIV-positive patients
  • No other concurrent drugs known to have histone deacetylase inhibitor activity (e.g., sodium valproate)
  • No other concurrent investigational agents
  • No other concurrent anticancer agents
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00112463

Sponsors and Collaborators
National Cancer Institute (NCI)
Principal Investigator: Paul Savage Wake Forest University Health Sciences
  More Information

Responsible Party: National Cancer Institute (NCI) Identifier: NCT00112463     History of Changes
Obsolete Identifiers: NCT01645683
Other Study ID Numbers: NCI-2012-01037
NCI-2012-01037 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
CCCWFU 71103 ( Other Identifier: Wake Forest University Health Sciences )
6319 ( Registry Identifier: CTEP )
U10CA081851 ( US NIH Grant/Contract Award Number )
P30CA012197 ( US NIH Grant/Contract Award Number )
Study First Received: June 2, 2005
Results First Received: April 4, 2017
Last Updated: April 4, 2017
Individual Participant Data  
Plan to Share IPD: No

Additional relevant MeSH terms:
Gastrointestinal Stromal Tumors
Sarcoma, Ewing
Neuroectodermal Tumors
Neuroectodermal Tumors, Primitive
Sarcoma, Alveolar Soft Part
Histiocytoma, Benign Fibrous
Histiocytoma, Malignant Fibrous
Sarcoma, Synovial
Neuroectodermal Tumors, Primitive, Peripheral
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms, Bone Tissue
Neoplasms, Connective Tissue
Neoplasms, Muscle Tissue
Gastrointestinal Neoplasms
Digestive System Neoplasms processed this record on May 25, 2017